Copyright
©The Author(s) 2019.
World J Gastroenterol. Feb 14, 2019; 25(6): 659-671
Published online Feb 14, 2019. doi: 10.3748/wjg.v25.i6.659
Published online Feb 14, 2019. doi: 10.3748/wjg.v25.i6.659
Figure 2 Overview of cancer surveillance in patients with primary sclerosing cholangitis, beginning at time of primary sclerosing cholangitis diagnosis.
This overview is based on recommendations from the American Association for the Study of Liver Disease practice guidelines[44]. CCA: Cholangiocarcinoma; GBC: Gallbladder carcinoma; HCC: Hepatocellular carcinoma; IBD: Inflammatory bowel disease; US: Ultrasound; PSC: Primary sclerosing cholangitis.
- Citation: Fung BM, Lindor KD, Tabibian JH. Cancer risk in primary sclerosing cholangitis: Epidemiology, prevention, and surveillance strategies. World J Gastroenterol 2019; 25(6): 659-671
- URL: https://www.wjgnet.com/1007-9327/full/v25/i6/659.htm
- DOI: https://dx.doi.org/10.3748/wjg.v25.i6.659